imvt: the income statement

MyFinsight

Immunovant, Inc. (IMVT)

For the quarter ending 2025-06-30, IMVT made $7,524K in revenue. -$120,613K in net income. Net profit margin of -1603.04%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2025-06-30
Provision for income taxes	913
Other income, net	1,187
Research and development	101,200
General and administrative	26,024
Total operating expenses	127,224
Interest income, net	6,337
Loss before provision for income taxes	-119,700
Net loss	-120,613

Net loss per common share - basic (in dollars per share)	-0.71
Net loss per common share - diluted (in dollars per share)	-0.71
Weighted-average common shares outstanding basic (in shares)	170,872,994
Weighted-average common shares outstanding diluted (in shares)	170,872,994

Unit: Thousand (K) dollars (except for numbers of shares and EPS)